1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A

Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A

SSZSE:002773
19.95
CNY
+0.19
(+0.96%)
18.84BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.89
2.15
2.52
2.91
3.19
3.36
3.73
3.79
3.94
3.7
4.32
4.86
4.97
- -
Basic EPS, GAAP
0.4
0.35
0.48
0.57
0.74
0.8
0.82
-0.31
0.46
0.98
1.14
1.3
1.26
- -
Free Cash Flow per Basic Share
0.33
0.26
0.44
0.77
0.52
-0.12
-0.17
-0.39
-0.08
0.62
1.18
1.37
1.34
- -
Dividend per Share
0.05
0.07
0.07
0.1
0.12
0.22
0.22
0.28
0.1
0.1
0.15
0.38
0.6
- -
Book Value per Share
1.95
2.04
2.88
3.31
4.04
4.66
5.28
6.25
6.62
7.51
8.49
9.41
10.09
10
Tangible Book Value per Share
1.7
1.81
2.65
3.06
3.61
3.74
3.78
5.64
6.24
7.08
8.04
8.97
9.64
9.49
Basic Weighted Avg Shares
780
780
824
873
872
869
873
870
915
915
916
916
923
924
Sales/Revenue/Turnover
1,477
1,675
2,074
2,540
2,786
2,917
3,257
3,295
3,605
3,389
3,957
4,453
4,585
- -
Operating Margin (%)
20.19
18.61
19.85
20.4
27.32
24.9
23.61
-17.42
14.08
27.63
29.46
28.63
28.26
- -
Depreciation Expense
58
67
65
63
65
74
93
118
149
158
223
230
238
- -
Net Income, GAAP
316
273
394
497
644
695
718
-270
421
897
1,045
1,191
1,163
- -
Effective Tax Rate (%)
14.31
18.11
13.01
11.91
15.58
13.07
14.01
- -
- -
15.96
16.43
12.98
15.53
- -
Profit Margin (%)
21.38
16.33
18.98
19.56
23.12
23.82
22.05
-8.19
11.68
26.46
26.4
26.75
25.36
- -
Working Capital
707
958
1,860
2,284
2,884
2,793
2,278
2,981
3,031
3,535
4,651
5,634
6,483
6,441
LT Debt
- -
- -
- -
- -
396
342
278
1
4
3
1
3
2
1
Total Equity
1,389
1,612
2,525
2,905
3,543
4,084
4,621
5,756
6,105
6,907
7,812
8,647
9,275
9,181
Return on Invested Capital (%)
23.35
17.61
18.05
17.49
19.01
16.24
14.86
- -
- -
13.04
14.26
14.54
12.91
- -
Return on Capital (%)
24.64
17.97
18.87
18.17
18.08
15.66
15.4
- -
- -
14.24
14.37
14.64
13.17
- -
Return on Common Equity (%)
25.62
18.45
19.24
18.38
19.98
18.22
16.5
-5.2
7.11
13.8
14.21
14.48
12.96
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
1
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
921
921
921
Market Capitalization
27,612
26,626
18,841

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
7,084
7,439
7,154
Cash, Cash Equivalents & STI
6,435
6,714
6,341
Accounts Receivable, Net
189
203
287
Inventories
407
413
405
Total Current Liabilities
602
586
713
Payables & Accruals
- -
- -
- -
ST Debt
2
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.02%
10.05%
7.26%
Free Cash Flow
-73.41%
-166.09%
-0.9%
Net Income, GAAP
-18.54%
-22.99%
-2.37%
Sales/Revenue/Turnover
8.53%
7.13%
2.98%
Total Cash Common Dividend
- -
- -
58.18%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,093
1,201
1,117
1,041
4,453
2025
1,199
1,255
- -
961
4,585
2026
1,046
1,133
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.41
0.35
0.31
0.24
1.3
2025
0.43
0.36
- -
0.14
1.26
2026
0.33
0.28
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.38
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xiao Ke
Full Time Employees
4,470
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.36, Shuxi Road Chengdu SI China 610037
IPO Date
Jun 26, 2015
Website
cnkh.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the discovery, creation, manufacturing, and distribution of biological products, traditional Chinese medicines, chemical pharmaceuticals, and medical devices. The company provides a range of treatments primarily targeting ophthalmic, central nervous system, digestive system, and endocrine system conditions. Its portfolio includes key drugs such as Conbercept for various macular degenerations and other eye diseases, alongside a pipeline actively developing innovative gene therapies and oncology solutions for global markets. Founded in 1996, the company is headquartered in Chengdu, China.